<i id='584D7AF3F3'><strike id='584D7AF3F3'><tt id='584D7AF3F3'><pre id='584D7AF3F3'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Psychedelics group wrestles with new pharma identity 
RSV shot was 90% effective at preventing hospitalizations in kids 
The high cost of giving birth even with insurance 
Just how do doctors, lawmakers, and the public define abortion? 
In age of alternative facts, a scholarly course on calling out crap 
Medicare drug price negotiation hearing pits pharma v Biden admin 
How one medical school became remarkably diverse 
Biden's 'march 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
First medicine developed to treat MASH expected to be approved soon 
At least 13 dead in Texas as scorching temps continue 
NEJM study link tiny plastics in blood vessels to heart problems 
Trump demands the U.S. pay no more for drugs than other countries … again 
IVF doctors demand details after CooperSurgical lawsuit 
Peter Hotez and the public health issue of online harassment 
